BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Katsiki N, Banach M, Mikhailidis DP. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic. Arch Med Sci 2020;16:485-9. [PMID: 32399093 DOI: 10.5114/aoms.2020.94503] [Cited by in Crossref: 50] [Cited by in F6Publishing: 56] [Article Influence: 16.7] [Reference Citation Analysis]
Number Citing Articles
1 Nandi R, Bhowmik D, Srivastava R, Prakash A, Kumar D. Discovering potential inhibitors against SARS-CoV-2 by targeting Nsp13 Helicase. J Biomol Struct Dyn 2022;40:12062-74. [PMID: 34455933 DOI: 10.1080/07391102.2021.1970024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Kowalska K, Sabatowska Z, Forycka J, Młynarska E, Franczyk B, Rysz J. The Influence of SARS-CoV-2 Infection on Lipid Metabolism—The Potential Use of Lipid-Lowering Agents in COVID-19 Management. Biomedicines 2022;10:2320. [DOI: 10.3390/biomedicines10092320] [Reference Citation Analysis]
3 Mahajan I, Ghose A, Gupta D, Manasvi M, Bhandari S, Das A, Sanchez E, Boussios S. COVID-19, Mucormycosis and Cancer: The Triple Threat-Hypothesis or Reality? J Pers Med 2022;12. [PMID: 35887616 DOI: 10.3390/jpm12071119] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 King A, Doyle KM. Implications of COVID-19 to Stroke Medicine: An Epidemiological and Pathophysiological Perspective. Curr Vasc Pharmacol 2022;20:333-40. [PMID: 36324222 DOI: 10.2174/1570161120666220428101337] [Reference Citation Analysis]
5 Liu C, Yan W, Shi J, Wang S, Peng A, Chen Y, Huang K. Biological Actions, Implications, and Cautions of Statins Therapy in COVID-19. Front Nutr 2022;9:927092. [DOI: 10.3389/fnut.2022.927092] [Reference Citation Analysis]
6 Radbakhsh S, Katsiki N, Santos RD, Mikhailidis DP, Mantzoros CS, Sahebkar A. Effects of statins on specialized pro-resolving mediators: An additional pathway leading to resolution of inflammation. Metabolism 2022;:155211. [PMID: 35533891 DOI: 10.1016/j.metabol.2022.155211] [Reference Citation Analysis]
7 Naik RR, Shakya AK, Aladwan SM, El-Tanani M. Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of COVID-19. Front Pharmacol 2022;13:806568. [PMID: 35444538 DOI: 10.3389/fphar.2022.806568] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
8 Liu H, Peck XY, Choong YK, Ng WS, Engl W, Raghuvamsi PV, Zhao ZW, Anand GS, Zhou Y, Sivaraman J, Xu Q, Wong S. Identification of putative binding interface of PI(3,5)P2 lipid on rice black-streaked dwarf virus (RBSDV) P10 protein. Virology 2022. [DOI: 10.1016/j.virol.2022.03.010] [Reference Citation Analysis]
9 Liu H, Gu H, Qu H, Bao W, Li Y, Cai D. Aberrant Cholesterol Metabolic Genes Regulation in a Negative Feedback Loop Induced by an Alphacoronavirus. Front Nutr 2022;9:870680. [DOI: 10.3389/fnut.2022.870680] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Devi KP, Pourkarim MR, Thijssen M, Sureda A, Khayatkashani M, Cismaru CA, Neagoe IB, Habtemariam S, Razmjouei S, Khayat Kashani HR. A perspective on the applications of furin inhibitors for the treatment of SARS-CoV-2. Pharmacol Rep 2022. [PMID: 35031970 DOI: 10.1007/s43440-021-00344-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
11 Perez-Lemus GR, Menéndez CA, Alvarado W, Byléhn F, de Pablo JJ. Toward wide-spectrum antivirals against coronaviruses: Molecular characterization of SARS-CoV-2 NSP13 helicase inhibitors. Sci Adv 2022;8:eabj4526. [PMID: 34995115 DOI: 10.1126/sciadv.abj4526] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
12 Schwab KO, Doerfer J. Sekundär verursachte Dyslipoproteinämien und Atheroskleroserisiko. Pädiatrische Fettstoffwechselstörungen und Atheroskleroserisiko – kompakt 2022. [DOI: 10.1007/978-3-662-63320-5_4] [Reference Citation Analysis]
13 Rizk JG, Wenziger C, Tran D, Hashemi L, Moradi H, Streja E, Ahluwalia A. Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19. Drugs 2021. [PMID: 34914085 DOI: 10.1007/s40265-021-01639-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
14 Rezabakhsh A, Sadat-Ebrahimi SR, Ala A, Nabavi SM, Banach M, Ghaffari S. A close-up view of dynamic biomarkers in the setting of COVID-19: Striking focus on cardiovascular system. J Cell Mol Med 2021. [PMID: 34894069 DOI: 10.1111/jcmm.17122] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Torres-Peña JD, Katsiki N, Perez-Martinez P. Could Statin Therapy Be Useful in Patients With Coronavirus Disease 2019 (COVID-19)? Front Cardiovasc Med 2021;8:775749. [PMID: 34778421 DOI: 10.3389/fcvm.2021.775749] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Jin H, He J, Dong C, Li B, Ma Z, Li B, Huang T, Fan J, He G, Zhao X. Altered Lipid Profile Is a Risk Factor for the Poor Progression of COVID-19: From Two Retrospective Cohorts. Front Cell Infect Microbiol 2021;11:712530. [PMID: 34660338 DOI: 10.3389/fcimb.2021.712530] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
17 Alketbi EH, Hamdy R, El-Kabalawy A, Juric V, Pignitter M, A Mosa K, Almehdi AM, El-Keblawy AA, Soliman SSM. Lipid-based therapies against SARS-CoV-2 infection. Rev Med Virol 2021;31:1-13. [PMID: 34546604 DOI: 10.1002/rmv.2214] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
18 Katsiki N, Gómez-Huelgas R, Mikhailidis DP, Pérez-Martínez P. Narrative review on clinical considerations for patients with diabetes and COVID-19: More questions than answers. Int J Clin Pract 2021;75:e14833. [PMID: 34510676 DOI: 10.1111/ijcp.14833] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Rath S, Perikala V, Jena AB, Dandapat J. Factors regulating dynamics of angiotensin-converting enzyme-2 (ACE2), the gateway of SARS-CoV-2: Epigenetic modifications and therapeutic interventions by epidrugs. Biomed Pharmacother 2021;143:112095. [PMID: 34479017 DOI: 10.1016/j.biopha.2021.112095] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
20 Kifle ZD. Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review. Metabol Open 2021;11:100116. [PMID: 34345815 DOI: 10.1016/j.metop.2021.100116] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Barberis E, Amede E, Tavecchia M, Marengo E, Cittone MG, Rizzi E, Pedrinelli AR, Tonello S, Minisini R, Pirisi M, Manfredi M, Sainaghi PP. Understanding protection from SARS-CoV-2 using metabolomics. Sci Rep 2021;11:13796. [PMID: 34226622 DOI: 10.1038/s41598-021-93260-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
22 Orlowski S, Mourad JJ, Gallo A, Bruckert E. Coronaviruses, cholesterol and statins: Involvement and application for Covid-19. Biochimie 2021;189:51-64. [PMID: 34153377 DOI: 10.1016/j.biochi.2021.06.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
23 Bhaskar S, Jovanovic S, Katyal A, Namboodiri NK, Chatzis D, Banach M. Is COVID-19 another case of the obesity paradox? Results from an international ecological study on behalf of the REPROGRAM Consortium Obesity study group. Arch Med Sci 2023;19:25-34. [PMID: 36817671 DOI: 10.5114/aoms/136447] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Opinc A, Brzezińska O, Makowska J. The impact of COVID-19 and healthcare system changes on the well-being of rheumatic patients. Reumatologia 2021;59:73-84. [PMID: 33976460 DOI: 10.5114/reum.2021.105424] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
25 O'Rourke RW, Lumeng CN. Pathways to Severe COVID-19 for People with Obesity. Obesity (Silver Spring) 2021;29:645-53. [PMID: 33270351 DOI: 10.1002/oby.23099] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
26 Torres-Peña JD, Pérez-Belmonte LM, Fuentes-Jiménez F, López Carmona MD, Pérez-Martinez P, López-Miranda J, Carrasco Sánchez FJ, Vargas Núñez JA, Del Corral Beamonte E, Magallanes Gamboa JO, González García A, González Moraleja J, Cortés Troncoso A, Taboada Martínez ML, Del Fidalgo Montero MDP, Seguí Ripol JM, Gil Sánchez R, Alegre González D, Boixeda R, Cortés Rodríguez B, Ena J, García García GM, Ventura Esteve A, Ramos Rincón JM, Gómez-Huelgas R; SEMI-COVID-19 Network. Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry. Drugs 2021;81:685-95. [PMID: 33782908 DOI: 10.1007/s40265-021-01498-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
27 Ghanei M. It is time to consider an anti-inflammatory therapy based on the pathophysiology of COVID-19 infection during the right time window? Arch Med Sci 2021;17:546-50. [PMID: 33747291 DOI: 10.5114/aoms/130647] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Lewek J, Jatczak-Pawlik I, Maciejewski M, Jankowski P, Banach M. COVID-19 and cardiovascular complications - preliminary results of the LATE-COVID study. Arch Med Sci 2021;17:818-22. [PMID: 34025853 DOI: 10.5114/aoms/134211] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
29 Parsamanesh N, Karami-Zarandi M, Banach M, Penson PE, Sahebkar A. Effects of statins on myocarditis: A review of underlying molecular mechanisms. Prog Cardiovasc Dis 2021;67:53-64. [PMID: 33621589 DOI: 10.1016/j.pcad.2021.02.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
30 Belančić A, Kresović A, Troskot Dijan M. Glucagon-like peptide-1 receptor agonists in the era of COVID-19: Friend or foe? Clin Obes 2021;11:e12439. [PMID: 33423388 DOI: 10.1111/cob.12439] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
31 Katsiki N, Banach M, Mikhailidis DP. More Good News on Statins and COVID-19. Am J Cardiol 2021;138:127-8. [PMID: 33164793 DOI: 10.1016/j.amjcard.2020.10.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
32 Tang Y, Hu L, Liu Y, Zhou B, Qin X, Ye J, Shen M, Wu Z, Zhang P. Possible mechanisms of cholesterol elevation aggravating COVID-19. Int J Med Sci 2021;18:3533-43. [PMID: 34522180 DOI: 10.7150/ijms.62021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
33 Gareeva DF, Musin TI, Pavlov VN, Davtyan PA, Ishmetov VS, Plotnikova MR, Pavlov AV, Cai B, Stricker P, Carvalho K, Zagidullin NS. Statins: unexpected help in COVID-19. Arter gipertenz 2020;26:509-517. [DOI: 10.18705/1607-419x-2020-26-5-509-517] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
34 Oz M, Lorke DE, Kabbani N. A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor. Pharmacol Ther 2021;221:107750. [PMID: 33275999 DOI: 10.1016/j.pharmthera.2020.107750] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
35 Kapoor N, Ghorai SM, Kushwaha PK, Shukla R, Aggarwal C, Bandichhor R. Plausible mechanisms explaining the role of cucurbitacins as potential therapeutic drugs against coronavirus 2019. Inform Med Unlocked 2020;21:100484. [PMID: 33251326 DOI: 10.1016/j.imu.2020.100484] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
36 Kočar E, Režen T, Rozman D. Cholesterol, lipoproteins, and COVID-19: Basic concepts and clinical applications. Biochim Biophys Acta Mol Cell Biol Lipids 2021;1866:158849. [PMID: 33157278 DOI: 10.1016/j.bbalip.2020.158849] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 15.3] [Reference Citation Analysis]
37 Petrovic V, Radenkovic D, Radenkovic G, Djordjevic V, Banach M. Pathophysiology of Cardiovascular Complications in COVID-19. Front Physiol 2020;11:575600. [PMID: 33162899 DOI: 10.3389/fphys.2020.575600] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
38 Frías Vargas M, Díaz Rodríguez A, Díaz Fernández B. [Lipid treatment in the period COVID-19]. Semergen 2020;46:497-502. [PMID: 32718781 DOI: 10.1016/j.semerg.2020.06.014] [Reference Citation Analysis]
39 Ganjali S, Bianconi V, Penson PE, Pirro M, Banach M, Watts GF, Sahebkar A. Commentary: Statins, COVID-19, and coronary artery disease: killing two birds with one stone. Metabolism 2020;113:154375. [PMID: 32976855 DOI: 10.1016/j.metabol.2020.154375] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]
40 Rethemiotaki I. A preliminary study of coronavirus disease 2019 in China: the impact of cardiovascular disease on death risk. Arch Med Sci Atheroscler Dis 2020;5:e219-23. [PMID: 33305058 DOI: 10.5114/amsad.2020.98918] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Bhaskar S, Bradley S, Chattu VK, Adisesh A, Nurtazina A, Kyrykbayeva S, Sakhamuri S, Moguilner S, Pandya S, Schroeder S, Banach M, Ray D. Telemedicine as the New Outpatient Clinic Gone Digital: Position Paper From the Pandemic Health System REsilience PROGRAM (REPROGRAM) International Consortium (Part 2). Front Public Health 2020;8:410. [PMID: 33014958 DOI: 10.3389/fpubh.2020.00410] [Cited by in Crossref: 65] [Cited by in F6Publishing: 75] [Article Influence: 21.7] [Reference Citation Analysis]
42 Momtazi-Borojeni AA, Banach M, Reiner Ž, Pirro M, Bianconi V, Al-Rasadi K, Sahebkar A. Interaction Between Coronavirus S-Protein and Human ACE2: Hints for Exploring Efficient Therapeutic Targets to Treat COVID-19. Angiology 2021;72:122-30. [PMID: 32864982 DOI: 10.1177/0003319720952284] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
43 Carlin C, Manor D. Adenovirus Reveals New Pathway for Cholesterol Egress from the Endolysosomal System. Int J Mol Sci 2020;21:E5808. [PMID: 32823559 DOI: 10.3390/ijms21165808] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
44 Weisberg E, Parent A, Yang PL, Sattler M, Liu Q, Liu Q, Wang J, Meng C, Buhrlage SJ, Gray N, Griffin JD. Repurposing of Kinase Inhibitors for Treatment of COVID-19. Pharm Res 2020;37:167. [PMID: 32778962 DOI: 10.1007/s11095-020-02851-7] [Cited by in Crossref: 72] [Cited by in F6Publishing: 59] [Article Influence: 24.0] [Reference Citation Analysis]
45 Poduri R, Joshi G, Jagadeesh G. Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. Cell Signal 2020;74:109721. [PMID: 32711111 DOI: 10.1016/j.cellsig.2020.109721] [Cited by in Crossref: 76] [Cited by in F6Publishing: 80] [Article Influence: 25.3] [Reference Citation Analysis]
46 Bhaskar S, Sinha A, Banach M, Mittoo S, Weissert R, Kass JS, Rajagopal S, Pai AR, Kutty S. Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper. Front Immunol. 2020;11:1648. [PMID: 32754159 DOI: 10.3389/fimmu.2020.01648] [Cited by in Crossref: 232] [Cited by in F6Publishing: 248] [Article Influence: 77.3] [Reference Citation Analysis]
47 Michaud V, Deodhar M, Arwood M, Al Rihani SB, Dow P, Turgeon J. ACE2 as a Therapeutic Target for COVID-19; its Role in Infectious Processes and Regulation by Modulators of the RAAS System. J Clin Med 2020;9:E2096. [PMID: 32635289 DOI: 10.3390/jcm9072096] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
48 Cismaru AC, Cismaru LG, Nabavi SF, Berindan-Neagoe I, Clementi E, Banach M, Nabavi SM. Game of "crowning" season 8: RAS and reproductive hormones in COVID-19 - can we end this viral series? Arch Med Sci 2021;17:275-84. [PMID: 33747262 DOI: 10.5114/aoms.2020.96604] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
49 Radenkovic D, Chawla S, Pirro M, Sahebkar A, Banach M. Cholesterol in Relation to COVID-19: Should We Care about It? J Clin Med 2020;9:E1909. [PMID: 32570882 DOI: 10.3390/jcm9061909] [Cited by in Crossref: 77] [Cited by in F6Publishing: 85] [Article Influence: 25.7] [Reference Citation Analysis]
50 Habtemariam S, Nabavi SF, Banach M, Berindan-Neagoe I, Sarkar K, Sil PC, Nabavi SM. Should We Try SARS-CoV-2 Helicase Inhibitors for COVID-19 Therapy? Arch Med Res 2020;51:733-5. [PMID: 32536457 DOI: 10.1016/j.arcmed.2020.05.024] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 12.7] [Reference Citation Analysis]
51 Abu-Farha M, Thanaraj TA, Qaddoumi MG, Hashem A, Abubaker J, Al-Mulla F. The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target. Int J Mol Sci 2020;21:E3544. [PMID: 32429572 DOI: 10.3390/ijms21103544] [Cited by in Crossref: 147] [Cited by in F6Publishing: 157] [Article Influence: 49.0] [Reference Citation Analysis]
52 Bianconi V, Bronzo P, Banach M, Sahebkar A, Mannarino MR, Pirro M. Particulate matter pollution and the COVID-19 outbreak: results from Italian regions and provinces. Arch Med Sci 2020;16:985-92. [PMID: 32863986 DOI: 10.5114/aoms.2020.95336] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 13.3] [Reference Citation Analysis]
53 Banach M, Penson PE, Fras Z, Vrablik M, Pella D, Reiner Ž, Nabavi SM, Sahebkar A, Kayikcioglu M, Daccord M; FH Europe and the International Lipid Expert Panel (ILEP). Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic. Pharmacol Res 2020;158:104891. [PMID: 32389859 DOI: 10.1016/j.phrs.2020.104891] [Cited by in Crossref: 44] [Cited by in F6Publishing: 49] [Article Influence: 14.7] [Reference Citation Analysis]
54 [DOI: 10.1101/2020.11.05.369264] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Reference Citation Analysis]